Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7380
    -0.0006 (-0.09%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    94,787.48
    -1,011.41 (-1.06%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6846
    +0.0003 (+0.04%)
     

Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher

Rexahn Pharmaceuticals, Inc. RNN was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.27 to $2.78 in the past one-month time frame.

The move came after the company announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has given positive view recommending orphan medicinal product (orphan drug) designation for RX-3117 to treat pancreatic cancer.

The company has seen one negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Rexahn Pharmaceuticals, Inc. Price

Rexahn Pharmaceuticals, Inc. Price | Rexahn Pharmaceuticals, Inc. Quote

ADVERTISEMENT

Rexahn Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.

Another stock worth considering in the Medical sector is Axovant Sciences Ltd. AXON which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Is RNN going up? Or down? Predict to see what others think: Up or Down

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Rexahn Pharmaceuticals, Inc. (RNN) : Free Stock Analysis Report
 
Axovant Sciences Ltd. (AXON) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research